Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2A

  1. Antonietta Franco
  2. Xiawei Dang
  3. Emily K Walton
  4. Joshua N Ho
  5. Barbara Zablocka
  6. Cindy Ly
  7. Timothy M Miller
  8. Robert H Baloh
  9. Michael E Shy
  10. Andrew S Yoo
  11. Gerald W Dorn II  Is a corresponding author
  1. Washington University School of Medicine, United States
  2. Mossakowski Medical Research Centre, Poland
  3. Cedars-Sinai Medical Center, United States
  4. Carver College of Medicine, University of Iowa, United States

Abstract

Charcot-Marie-Tooth disease type 2A (CMT2A) is an untreatable childhood peripheral neuropathy caused by mutations of the mitochondrial fusion protein, mitofusin (MFN) 2. Here, pharmacological activation of endogenous normal mitofusins overcame dominant inhibitory effects of CMT2A mutants in reprogrammed human patient motor neurons, reversing hallmark mitochondrial stasis and fragmentation independent of causal MFN2 mutation. In mice expressing human MFN2 T105M, intermittent mitofusin activation with a small molecule, MiM111, normalized CMT2A neuromuscular dysfunction, reversed pre-treatment axon and skeletal myocyte atrophy, and enhanced axon regrowth by increasing mitochondrial transport within peripheral axons and promoting in vivo mitochondrial localization to neuromuscular junctional synapses. MiM111-treated MFN2 T105M mouse neurons exhibited accelerated primary outgrowth and greater post-axotomy regrowth, linked to enhanced mitochondrial motility. MiM111 is the first pre-clinical candidate for CMT2A.

Data availability

All data generated or analyzed during this study are included in the manuscript.

Article and author information

Author details

  1. Antonietta Franco

    Department of Internal Medicine, Pharmacogenomics, Washington University School of Medicine, St Louis, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5487-1800
  2. Xiawei Dang

    Department of Internal Medicine, Pharmacogenomics, Washington University School of Medicine, St Louis, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0343-7107
  3. Emily K Walton

    Department of Internal Medicine, Pharmacogenomics, Washington University School of Medicine, St Louis, United States
    Competing interests
    No competing interests declared.
  4. Joshua N Ho

    Department of Developmental Biology, Washington University School of Medicine, St Louis, United States
    Competing interests
    No competing interests declared.
  5. Barbara Zablocka

    Molecular Biology Unit, Mossakowski Medical Research Centre, Warsaw, Poland
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2204-5184
  6. Cindy Ly

    Department of Neurology, Washington University School of Medicine, St Louis, United States
    Competing interests
    No competing interests declared.
  7. Timothy M Miller

    Department of Neurology, Washington University School of Medicine, St Louis, United States
    Competing interests
    No competing interests declared.
  8. Robert H Baloh

    Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, United States
    Competing interests
    No competing interests declared.
  9. Michael E Shy

    Department of Neurology, Carver College of Medicine, University of Iowa, Iowa City, United States
    Competing interests
    No competing interests declared.
  10. Andrew S Yoo

    Department of Developmental Biology, Washington University School of Medicine, St Louis, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0304-3247
  11. Gerald W Dorn II

    Department of Internal Medicine, Pharmacogenomics, Washington University School of Medicine, St Louis, United States
    For correspondence
    gdorn@wustl.edu
    Competing interests
    Gerald W Dorn II, G.W.D. is an inventor on patent applications PCT/US18/028514 submitted by Washington University and PCT/US19/46356 submitted by Mitochondria Emotion, Inc that cover the use of small molecule mitofusin agonists to treat chronic neurodegenerative diseases, and is a founder of Mitochondria in Motion, Inc., a Saint Louis based biotech R&D company focused on enhancing mitochondrial trafficking and fitness in neurodegenerative diseases..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8995-1624

Funding

NIH (R35HL135736)

  • Gerald W Dorn II

NIH (R41NS113642)

  • Gerald W Dorn II

NIH (R41NS115184)

  • Gerald W Dorn II

Muscular Dystrophy Association (628906)

  • Gerald W Dorn II

McDonnell Center for Cellular and Molecular (Neurobiology Postdoctoral Fellowship)

  • Antonietta Franco

Harrington Discovery Institute (Scholar-Innovator awardee)

  • Gerald W Dorn II

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All experimental procedures were approved by Washington University in St. Louis School of Medicine Animal Studies Committee; IACUC protocol number 19-0910, Exp:12/16/2022 (Gerald Dorn, PI).

Copyright

© 2020, Franco et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,132
    views
  • 531
    downloads
  • 41
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Antonietta Franco
  2. Xiawei Dang
  3. Emily K Walton
  4. Joshua N Ho
  5. Barbara Zablocka
  6. Cindy Ly
  7. Timothy M Miller
  8. Robert H Baloh
  9. Michael E Shy
  10. Andrew S Yoo
  11. Gerald W Dorn II
(2020)
Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2A
eLife 9:e61119.
https://doi.org/10.7554/eLife.61119

Share this article

https://doi.org/10.7554/eLife.61119

Further reading

    1. Cell Biology
    Joan Chang, Adam Pickard ... Karl E Kadler
    Research Article

    Collagen-I fibrillogenesis is crucial to health and development, where dysregulation is a hallmark of fibroproliferative diseases. Here, we show that collagen-I fibril assembly required a functional endocytic system that recycles collagen-I to assemble new fibrils. Endogenous collagen production was not required for fibrillogenesis if exogenous collagen was available, but the circadian-regulated vacuolar protein sorting (VPS) 33b and collagen-binding integrin α11 subunit were crucial to fibrillogenesis. Cells lacking VPS33B secrete soluble collagen-I protomers but were deficient in fibril formation, thus secretion and assembly are separately controlled. Overexpression of VPS33B led to loss of fibril rhythmicity and overabundance of fibrils, which was mediated through integrin α11β1. Endocytic recycling of collagen-I was enhanced in human fibroblasts isolated from idiopathic pulmonary fibrosis, where VPS33B and integrin α11 subunit were overexpressed at the fibrogenic front; this correlation between VPS33B, integrin α11 subunit, and abnormal collagen deposition was also observed in samples from patients with chronic skin wounds. In conclusion, our study showed that circadian-regulated endocytic recycling is central to homeostatic assembly of collagen fibrils and is disrupted in diseases.

    1. Cell Biology
    Chun-Wei Chen, Jeffery B Chavez ... Bruce J Nicholson
    Research Article Updated

    Endometriosis is a debilitating disease affecting 190 million women worldwide and the greatest single contributor to infertility. The most broadly accepted etiology is that uterine endometrial cells retrogradely enter the peritoneum during menses, and implant and form invasive lesions in a process analogous to cancer metastasis. However, over 90% of women suffer retrograde menstruation, but only 10% develop endometriosis, and debate continues as to whether the underlying defect is endometrial or peritoneal. Processes implicated in invasion include: enhanced motility; adhesion to, and formation of gap junctions with, the target tissue. Endometrial stromal (ESCs) from 22 endometriosis patients at different disease stages show much greater invasiveness across mesothelial (or endothelial) monolayers than ESCs from 22 control subjects, which is further enhanced by the presence of EECs. This is due to the enhanced responsiveness of endometriosis ESCs to the mesothelium, which induces migration and gap junction coupling. ESC-PMC gap junction coupling is shown to be required for invasion, while coupling between PMCs enhances mesothelial barrier breakdown.